CD274 and familial pancreatic carcinoma: In this work, we demonstrate that PD-L1 is a substrate of NEK2, and combinatorial inhibition of NEK2 and PD-L1 largely improves the therapeutic efficacy of pancreatic cancer in preclinical models.